Anthera Pharmaceuticals, Inc. (ANTH) Analysts See $-0.82 EPS

February 5, 2018 - By Kurt Siggers

 Anthera Pharmaceuticals, Inc. (ANTH) Analysts See $ 0.82 EPS

Analysts expect Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report $-0.82 EPS on February, 26.They anticipate $2.06 EPS change or 71.53 % from last quarter’s $-2.88 EPS. After having $-0.58 EPS previously, Anthera Pharmaceuticals, Inc.’s analysts see 41.38 % EPS growth. The stock decreased 2.24% or $0.035 during the last trading session, reaching $1.525. About 159,337 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 93.94% since February 5, 2017 and is downtrending. It has underperformed by 110.64% the S&P500.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

Among 6 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Anthera Pharmaceuticals had 17 analyst reports since August 13, 2015 according to SRatingsIntel. On Friday, July 8 the stock rating was initiated by H.C. Wainwright with “Buy”. The firm has “Neutral” rating by Citigroup given on Thursday, December 29. Jefferies maintained it with “Hold” rating and $2.2500 target in Sunday, August 6 report. On Friday, February 19 the stock rating was reinitiated by Jefferies with “Buy”. The stock has “Buy” rating by Suntrust Robinson on Wednesday, September 9. The firm has “Buy” rating by Citigroup given on Thursday, September 17. The firm earned “Buy” rating on Wednesday, September 9 by SunTrust. Piper Jaffray maintained the stock with “Overweight” rating in Thursday, December 29 report. Jefferies downgraded the shares of ANTH in report on Thursday, December 29 to “Hold” rating. Piper Jaffray maintained the shares of ANTH in report on Monday, January 22 with “Buy” rating.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $21.12 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

More important recent Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) news were published by: Globenewswire.com which released: “Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of …” on February 05, 2018, also Globenewswire.com published article titled: “Anthera Pharmaceuticals Announces Second Closing of $15 Million Private …”, Globenewswire.com published: “Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders” on January 08, 2018. More interesting news about Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was released by: Nasdaq.com and their article: “The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne …” with publication date: January 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: